FDA

News

Sarepta shares yo-yo as FDA places hold on Duchenne trial

Shares in Sarepta came under pressure after the biotech said it had temporarily halted a clinical trial of its new-generation Duchenne muscular dystrophy candidate, after a patient had a se

Market Access

US frets over pharma supply chain security

The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and regulatory inspections became difficult to carry out.

News

FDA panel turns down Acadia's Nuplazid for Alzheimer's psych...

Acadia Pharma's attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer's disease-related psychosis have suffered another major setback.

Market Access

Six months after authorization, what do we know about Paxlov...

It has now been over six months since the

Market Access

FDA’s treatment of China-developed drugs spurs demands for m...

China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the global pipeline.

News

Genetic engineeering concept with 3d rendering robotic hand editing dna helix

Second unanimous FDA adcomm vote boosts bluebird bio

bluebird bio started last week on tenterhooks, as FDA advisors cast their eyes over data for two gene therapy candidates that are key to its future as a commercially viable concern.

Sarepta shares yo-yo as FDA places hold on Duchenne trial

US frets over pharma supply chain security

FDA panel turns down Acadia's Nuplazid for Alzheimer's psych...

Six months after authorization, what do we know about Paxlov...

FDA’s treatment of China-developed drugs spurs demands for m...

Second unanimous FDA adcomm vote boosts bluebird bio

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks